Current usage of pembrolizumab in triple negative breast cancer (TNBC)
- Author(s)
- O'Rourke, H; Hart, C; De Boer, RH;
- Details
- Publication Year 2024-05,Volume 24,Issue #5,Page 253-261
- Journal Title
- Expert Review of Anticancer Therapy
- Publication Type
- Review
- Abstract
- INTRODUCTION: The use of immune checkpoint inhibitors (ICI) targeting the PD-1/PD-L1 pathway has changed the landscape in the treatment of triple negative breast cancer (TNBC). The ICI pembrolizumab in combination with chemotherapy now forms a standard of care for the treatment of advanced PD-L1 positive TNBC and as part of neoadjuvant therapy for high-risk early-stage disease. Evidence in this space is rapidly advancing. AREAS COVERED: This review aims to highlight the evolving role of immunotherapy in TNBC management and to discuss current challenges. The studies in this review were searched from PubMed and ClinicalTrials.gov. EXPERT OPINION: The KEYNOTE-522 trial demonstrated that the addition of peri-operative pembrolizumab to neoadjuvant chemotherapy improves patient outcomes in early-stage TNBC. However, critical questions remain including how to select which patients truly gain benefit from the addition of pembrolizumab; the optimal duration of therapy, and the optimal adjuvant therapy depending on pathologic response.
- Publisher
- Taylor & Francis
- Keywords
- Humans; *Triple Negative Breast Neoplasms/drug therapy/pathology; *Antibodies, Monoclonal, Humanized/administration & dosage/pharmacology; Female; *Neoadjuvant Therapy/methods; *Immune Checkpoint Inhibitors/administration & dosage/pharmacology; Antineoplastic Combined Chemotherapy Protocols/pharmacology/administration &; dosage; Neoplasm Staging; Immunotherapy/methods; B7-H1 Antigen/antagonists & inhibitors; Patient Selection; Antineoplastic Agents, Immunological/administration & dosage/pharmacology; Chemotherapy, Adjuvant/methods; *Programmed Cell Death 1 Receptor; Tnbc; Triple negative breast cancer; biomarker; immunotherapy; metastatic; neoadjuvant; pembrolizumab
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.1080/14737140.2024.2341729
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-07-17 03:02:38
Last Modified: 2024-07-17 03:11:20